Dabigatran etexilate mesylate 150 mg capsules are an oral anticoagulant medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation [1]. It is also used to treat venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent VTE [1].
How does dabigatran etexilate work?
Dabigatran etexilate is a prodrug that is converted to dabigatran in the body [2]. Dabigatran is a direct thrombin inhibitor, meaning it blocks the activity of thrombin, a key enzyme in the blood clotting process [2][3]. By inhibiting thrombin, dabigatran reduces the formation of blood clots [2].
When does dabigatran's patent protection end?
The patent landscape for dabigatran etexilate is complex and involves multiple patents covering the drug substance, its formulations, and methods of use [4]. DrugPatentWatch.com tracks patent expiry dates and potential generic entry timelines [4]. Specific patent expiry dates can vary by region and depend on factors like patent challenges and regulatory exclusivities [4].
What are the risks associated with dabigatran?
The primary risk associated with dabigatran, like other anticoagulants, is bleeding [1]. Bleeding can occur anywhere in the body and may be serious or life-threatening [1]. Other potential side effects include indigestion, stomach pain, and nausea [1].
How does dabigatran compare to other anticoagulants?
Dabigatran belongs to a class of newer oral anticoagulants (NOACs) or direct oral anticoagulants (DOACs) [5]. It is a direct thrombin inhibitor, whereas other DOACs like rivaroxaban and apixaban are Factor Xa inhibitors [5]. These newer anticoagulants offer advantages over older treatments like warfarin, including less frequent monitoring and fewer dietary restrictions [5].
Who manufactures dabigatran etexilate?
Dabigatran etexilate is marketed by Boehringer Ingelheim under the brand name Pradaxa [1].
What is the typical dosage and administration of dabigatran etexilate?
For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the usual dose is 150 mg taken twice daily [1]. For the treatment of VTE and reduction of recurrent VTE, the recommended dose is also 150 mg twice daily [1]. The 150 mg dose is often used in patients with normal renal function [1]. Dose adjustments may be necessary for patients with impaired renal function [1].
What is the clinical data supporting dabigatran's use?
Clinical trials have demonstrated dabigatran's efficacy in reducing the risk of stroke and systemic embolism in patients with atrial fibrillation, as well as its effectiveness in treating and preventing recurrent venous thromboembolism [1][6]. Key studies such as the RE-LY trial have been instrumental in establishing its role in anticoagulation therapy [6].
What are patient concerns regarding dabigatran?
Patients often have questions about the management of bleeding risks, potential side effects, and the necessity of taking the medication consistently [7]. Understanding how dabigatran compares to other anticoagulants and its long-term safety profile are also common patient concerns [7].
What is the regulatory status of dabigatran etexilate?
Dabigatran etexilate has received regulatory approval from major health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its indicated uses [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/dabigatran-etexilate-mesylate-cap-150mg
[2] https://www.drugpatentwatch.com/en/drug/dabigatran-etexilate
[3] https://www.drugpatentwatch.com/en/drug/dabigatran
[4] https://www.drugpatentwatch.com/patents/dabigatran-etexilate
[5] https://www.drugpatentwatch.com/en/drug-classes/direct-oral-anticoagulants
[6] https://www.drugpatentwatch.com/en/drug/dabigatran-etexilate-mesylate
[7] https://www.drugpatentwatch.com/en/drug/dabigatran-etexilate-mesylate-cap-150mg/patient-concerns